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Abstract
Purpose Treatment with the radiolabelled somatostatin
analogue 177Lu-octreotate results in tumour remission in
47% of patients with gastroenteropancreatic neuroendocrine
tumours. Adding capecitabine to 177Lu-octreotate, as a
radio-sensitiser, may enhance these anti-tumour effects. We
now present the short-term toxicity profile of this novel
combination.
Methods Seven patients were treated with 7.4 GBq 177Lu-
octreotate and capecitabine (1650 mg/m2 per day) for
2 weeks with an intended number of four cycles. Toxicity,
and especially haematological and renal parameters, were
monitored on a weekly basis for the first two cycles and 4
and 6 weeks after subsequent cycles.
Results None of the patients had hand-foot syndrome. One
patient had grade 1 stomatitis occurring after one of four
cycles. Grade 3 or 4 leukopenia or neutropenia did not
occur. One patient had grade 3 anaemia, but none had grade
4 anaemia. One patient had grade 2 thrombocytopenia after
the fourth cycle, and one had grade 3 thrombocytopenia.
Grade 4 thrombocytopenia did not occur. No significant
changes in serum creatinine levels were observed. None of
the patients had symptoms of cardiac ischaemia.
Conclusions Treatment with the combination of 177Lu-
octreotate and capecitabine was feasible and safe consider-
ing acute and subacute side effects. We therefore started a
randomised, controlled clinical trial to compare this com-
bination with 177Lu-octreotate as single agent with regard to
anti-tumour effects and side effects.
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Introduction
Peptide receptor radionuclide therapy (PRRT) with radio-
labelled somatostatin analogues can be very rewarding in
patients with inoperable somatostatin receptor positive
gastroenteropancreatic neuroendocrine tumours (GEP
NETs). Treatment with the radiolabelled analogue [177Lu-
DOTA0, Tyr3]octreotate (177Lu-octreotate) resulted in tu-
mour remission in 47% of 125 patients, and the median
time to progression had not been reached after 36 months of
follow-up [1]. The most frequently occurring short-term
side effects of this treatment were mild reversible alopecia
in 64% of patients, nausea in 31%, vomiting in 14% and an
increase in pain in tumour-involved regions in 12%. WHO
haematological toxicity in 131 patients treated with 177Lu-
octreotate was as follows: Hb grade 3 and 4 in 0.4 and
0.0%, leukopenia grade 3 and 4 in 1.3 and 0.0% and
thrombocytopenia grade 3 and 4 in 1.5 and 0.2%.
Although the anti-tumour effects of therapy with 177Lu-
octreotate are promising and serious side effects are rare,
further studies are needed to find treatments that are more
effective and still have acceptable side effects. One option
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for improvement is to use combinations of a radiolabelled
somatostatin analogue with chemotherapeutic agents as
radio-sensitiser. Candidate drugs for this purpose are 5-
fluorouracil (5-FU) and capecitabine, which is an oral
prodrug of 5-FU. For 5-FU, the additional effect to ra-
diation therapy has been demonstrated: The combination
of external beam radiation therapy with 5-FU resulted in
better anti-tumour effects than external beam radiation
therapy alone in patients with cancers of stomach, pancreas,
large bowel, rectum, head and neck and oesophagus
(mostly with cisplatin added as well). Moreover, chemo-
radiotherapy with 5-FU is also successfully used in anal
and bladder cancers (see [2] for review). External beam
radiation therapy with capecitabine was as effective as
external beam radiation therapy with intravenous 5-FU in
patients with locally advanced rectal carcinoma, but
treatment with capecitabine is more convenient for patients,
as it is an oral drug [3, 4]. Most common specific side
effects of capecitabine are hand-foot syndrome and stoma-
titis. These side effects occur frequently when capecitabine
is used in a dose of 2,500 mg/m2 per day in chemotherapy
regimens, either as single agent or in combination with
other chemotherapeutic agents. When using capecitabine as
radio-sensitiser, lower doses (1,600–2,000 mg/m2 per day)
are administered, and hand-foot syndrome and stomatitis
are less frequent. Another known, but rather infrequent,
side effect of capecitabine and related drugs is cardiac
ischaemia. This can result in myocardial infarction, also in
patients without a previous history of cardiac disease [5].
Most data on the combination of radiation therapy and 5-
FU or capecitabine were derived from studies using
external beam radiation therapy. Few data have been
published about 5-FU or capecitabine in combination with
radionuclide-derived radiation therapy with radiolabelled
peptides or antibodies. Wong et al. [6] reported that
treatment with 90Y-labelled antibodies and 5-FU was safe
in patients with metastasised colorectal cancer. PRRT with
[111In-DTPA0]octreotide in combination with 5-FU resulted
in symptomatic improvement in 71% of patients with
neuroendocrine tumours [7]. This is much more than 13
out of 38 patients (34%) with symptomatic improvement
published by Valkema et al. [8] who had not used 5-FU
during PRRT with [111In-DTPA0]octreotide. We were
therefore interested in combining 177Lu-octreotate with
capecitabine in treating patients with GEP NETs, as this
might result in better treatment outcomes. A possible
drawback could be an increase in side effects. We therefore
started a pilot study to investigate this combination.
We here present data on the acute toxicity profile of
177Lu-octreotate in combination with capecitabine in seven
patients. We monitored side effects including nausea,
vomiting, chest pain, hand-foot syndrome and stomatitis,
haematological side effects and acute side effects on
kidneys and liver: this to evaluate if this new combination
is safe and feasible in patients.
Materials and methods
Patients
Seven patients with metastasised GEP NETs were studied.
All patients had measurable disease. All patients had
tumour tissue uptake with [111In-DTPA0] octreotide scin-
tigraphy (OctreoScan®) that was on average equal to or
higher than uptake in normal hepatic tissue on planar
images. Patients with known somatostatin receptor-negative
lesions were excluded. Patients had not been treated with
other radiolabelled somatostatin analogues before. Prereq-
uisites for the first treatment were haemoglobin (Hb)
≥5.5 mmol/l, WBC ≥2×109/l, platelets ≥100×109/l, serum
creatinine ≤150 μmol/l and 24-h urine creatinine clearance
≥50 ml/min, and Karnofsky performance score ≥60. Haema-
tological criteria for further treatments were: Hb ≥5.0 mmol/l,
WBC ≥2×109/l, platelets ≥75×109/l. All other criteria for re-
treatment were identical. All patients gave written informed
consent to participate in the study, which was approved by the
local medical ethical committee.
Methods
[DOTA0,Tyr3]octreotate was obtained from Mallinckrodt
(St Louis, MO, USA). 177LuCl3 was obtained from NRG
(Petten, The Netherlands) and was distributed by IDB-
Holland (Baarle-Nassau, The Netherlands). 177Lu-octreotate
was locally prepared as described previously [9].
Granisetron 3 mg was injected intravenously 30 min
before starting the infusion of 177Lu-octreotate. To reduce
radiation dose to the kidneys, an infusion of amino acids
(arginine 2.5% and lysine 2.5%) was also started 30 min
before the administration of the radiopharmaceutical and
lasted 4 h. Via a second pump system, the radiopharma-
ceutical was co-administered. Cycle doses were 7.4 GBq
injected in 30 min. The interval between treatments was
6–10 weeks. Patients were treated up to an intended cumu-
lative dose of 29.6 GBq.
Capecitabine (Xeloda®; Roche, Basel, Switzerland)
1,650 mg/m2 per day, divided over two doses was adminis-
tered orally, starting on the day of treatment with 177Lu-
octreotate and continuing for 14 days. Patients were instructed
to report any signs of hand-foot syndrome, stomatitis or other
side effects.
Routine haematology, liver and kidney function tests
were performed after each therapy. This was performed
every week after the first and second treatment cycle. After
subsequent cycles, blood tests were performed at 4 and
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6 weeks after the treatment. Figure 1 depicts the treatment
schedule including blood tests.
Results
Seven male patients were studied. All had metastasised
GEP NETs (three non-functioning pancreatic NETs, four
carcinoid tumours). Six had progressive disease, demon-
strated within 12 months before start of treatment. In one
patient, some growth occurred before start (interval be-
tween scans of 2 months), but this did not classify as
progressive disease according to Southwest oncology group
criteria. In this patient, treatment was started because of a
large hepatic tumour load. Age at start ranged from 36 to
67 years (median 62 years). None of the patients had been
treated with capecitabine or other chemotherapeutic agents
before.
Twenty-six treatment cycles were given: Six patients
received four cycles; in one patient, treatment was stopped
after two cycles because of clinically progressive disease.
Side effects within 24 h after administration were: nausea
with vomiting, reported by one patient after one cycle. Two
patients had an increase in diarrhoea (3 of 26 cycles).
Increase in pain was not reported by any of the patients.
Patients also reported subacute side effects in the weeks
after the treatment: Five patients had nausea at home (7 of
26 cycles), two patients vomited (5 of 26 cycles). Two
patients noticed an increase in pain in tumour-involved
areas (2 of 26 cycles). Six patients experienced some
fatigue after a treatment cycle (7 of 26 cycles). Mild
alopecia was observed in four patients.
The patients were also asked to report any side effects
that are more specific for capecitabine: None of the patients
had signs or symptoms of hand-foot syndrome. One patient
mentioned that after the second treatment, the oral mucosa
was a bit more sensitive than usual, but no mucosal
abnormalities were seen (grade 1 stomatitis). None of the
other patients had complaints of stomatitis (Table 1). None
of the patients had chest pains. One patient with a serotonin
producing metastasised midgut carcinoid developed mild
oedema of the lower extremities. This was due to severely
progressive tricuspid valve insufficiency proven by a
cardiac ultrasound. Another patient developed oedema of
the legs caused by compression of the inferior vena cava.
None of the other patients had symptoms of heart failure.
Haematological toxicity is summarised in Table 2. Grade
3 or 4 leukopenia or neutropenia did not occur. One patient
had grade 3 anaemia (Hb 4.9 mmol/l) after the second
cycle, which resolved to grade 2 spontaneously 1 week
later. In this patient, treatment was stopped after two cycles
because of clear clinical progression of disease. Grade 4
anaemia did not occur. One patient had grade 2 thrombo-
cytopenia (72×109/l) after the fourth treatment. In one
patient, platelet count dropped to 36×109/l (grade 3
Table 1 Capecitabine-specific toxicity of treatment with 177Lu-
octreotate and capecitabine
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Hand-foot syndrome 0 0 0 NA
Stomatitis 1a 0 0 0
Numbers are patient-based (7 patients and 26 treatment cycles).
NA Not applicable
a After second cycle only
Table 2 Toxicity of treatment with 177Lu-octreotate and capecitabine
WHO Toxicity Grade 3 Grade 4
Platelets 1a 0
White blood cells 0 0
Neutrophil count 0 0
Haemoglobin 1b 0
Serum creatinine 0 0
Numbers are patient-based (7 patients and 26 treatment cycles).
a This patient developed grade 3 thrombocytopenia after the third and
fourth cycles.
b This patients had grade 3 anaemia (Hb 4.9 mmol/l) on one occasion
after the second treatment, which spontaneously resolved to grade 2
1 week later.
Fig. 1 Time schedule of treatment with 177Lu-octreotate and capecitabine
and follow-up during treatment. Each regular treatment cycle consisted
of an injection of 177Lu-octreotate (7.4 GBq) and of capecitabine
(1650 mg/m2 per day) for 2 weeks. Blood tests were performed at 4 and
6 weeks after start of a treatment cycle. In this pilot study, blood tests
were done every week only after the first and second cycles. The next
treatment cycle was given 6 to 10 weeks later. The intended number of
cycles was four
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toxicity) after the third cycle. After recovery of platelet
count to 93×109/l, therapy was resumed with half a dose of
177Lu-octreotate (3.7 GBq) and the normal dose of
capecitabine. Subsequently, platelet count again dropped
to 37×109/l. Treatment with 177Lu-octreotate was then
stopped (cumulative dose 25.6 GBq) because the patient
was deteriorating clinically and progression of disease was
documented on CT scan. Grade 4 thrombocytopenia did not
occur.
The course of haematological parameters and serum
creatinine levels are shown in Fig. 2. Platelet counts at
4 weeks after treatment were consistently lower than
baseline counts or counts at 6 weeks after the same
treatment. No changes were noted in serum creatinine
levels (no grade 2 or higher toxicity). No changes in liver
function tests occurred that could be attributed to the
treatment. Liver function tests deteriorated in the patient
with progressive disease despite two treatment cycles.
Although not the subject of this study, it is reassuring to
see that the treatment with the combination of 177Lu-
octreotate and capecitabine resulted in tumour size reduc-
tion in the first patient we treated (Fig. 3).
Discussion
PRRT with 177Lu-octreotate as single agent is effective in
patients with somatostatin receptor positive gastroentero-
pancreatic neuroendocrine tumours. However, strategies to
increase the efficacy of such treatment should be inves-
tigated. One possible way to improve these effects is
combining 177Lu-octreotate with chemotherapeutic agents
as radio-sensitiser. Capecitabine is often used as radio-
sensitiser with external beam radiation therapy. It has
attractive features for combining with radiation therapy:
Capecitabine is an oral prodrug of 5-FU and has to be
Fig. 2 Course of haematologi-
cal parameters and serum creat-
inine levels in seven patients
during and after treatments with
177Lu-octreotate and capecita-
bine (mean±standard error of
mean). Time axis: 0 represent
baseline values, x·y: x represents
treatment cycle, y represents
weeks after treatment. Data after
treatments 3 and 4 are based
on six patients
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converted to its active form after three enzymatic converting
steps. The third step is by the enzyme thymidine phosphor-
ylase (TP). Several types of malignant cells have high
expression of TP, and this can result in higher concentrations
of the active form (i.e. 5-FU) in tumour cells compared to
non-malignant cells [10]. Moreover, TP expression is
induced by radiation [11], which can again result in higher
concentrations of 5-FU in irradiated cells. These features
are also attractive for combining capecitabine with radio-
nuclide-derived radiation therapy, like PRRT.
To our knowledge, no studies have so far been published
that describe the combination of capecitabine with a
somatostatin analogue labelled with a beta-emitting isotope,
like 177Lu-octreotate, with regard to side effects. Based on
the findings from a pilot study to evaluate the safeness and
feasibility of this combination, we intended tomake a decision
to start or reject a randomised clinical trial comparing 177Lu-
octreotate as single agent with 177Lu-octreotate in combina-
tion with capecitabine.
Haematological toxicity was infrequent. One patient had
grade 2 thrombocytopenia after the fourth cycle. In one
patient, WHO grade 3 thrombocytopenia occurred after the
third and fourth cycles. In another patient, haemoglobin
was 4.9 mmol/l on one occasion (WHO grade 3 anaemia)
after the second cycle, which improved within 1 week to
grade 2 anaemia.
No acute renal toxicity was observed in these patients
based on measured serum creatinine levels. Of course,
some subtle side effects on glomerular filtration rate or
tubular function, which may only be demonstrated with
more sensitive methods, like 99mTc-DTPA or 99mTc-MAG3,
cannot be ruled out. However, based on serum creatinine
levels alone, we may conclude that there was no clinically
relevant acute renal toxicity.
None of the patients had hand-foot syndrome, and one
patient had a more sensitive oral mucosa, but grade 2 or
more stomatitis was not noted. The low frequency of these
side effects of capecitabine in our group can be explained
by the relatively low dose (approximately 825 mg/m2 bid)
used in this and other radio-sensitising studies. This is an
important characteristic, as ideally, we do not want to
provoke side effects that have a serious impact on quality of
life in these patients who usually have a life expectancy of
several years. Furthermore, nausea, vomiting and hair loss
were observed, but percentages in the group treated with
the combination are similar to those after treatment with
177Lu-octreotate alone. None of the patients had symptoms
of cardiac ischaemia or heart failure that could be attributed
to capecitabine.
Of note is that so far, only acute and subacute side
effects could be registered. No data are known yet about
long-term side effects. The patients treated with the
combination of 177Lu-octreotate and capecitabine will
therefore also be closely monitored in the future to reveal
potential late toxic effects, e.g. on kidney function and bone
marrow. The patients will undergo blood tests every
Fig. 3 The first patient treated
with 177Lu-octreotate and cape-
citabine was a 36-year-old man
with a metastasised pancreatic
neuroendocrine tumour. Images
in the left panel present the
tumours at baseline; the right
panel presents the situation
3 months after the fourth cycle.
The patient had a partial
remission
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6 months and will also collect urine for 24 h to determine
creatinine clearance and proteinuria.
Based on these findings, we conclude that the combina-
tion of 177Lu-octreotate with capecitabine is safe and
feasible in patients with GEP NETs with regard to short-
term side effects. We recently started a randomised controlled
clinical trial comparing treatment with 177Lu-octreotate alone
to treatment with 177Lu-octreotate and capecitabine. Ulti-
mately, the results of that study will provide final data about
differences in anti-tumour effects and toxicity profiles
between these treatments, also on the longer term.
Open Access This article is distributed under the terms of the
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